EA
BMRN icon

Emerald Acquisition’s BioMarin Pharmaceuticals BMRN Stock Holding History

Emerald Acquisition’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$9.37M Buy
101,253
+78,252
+340% +$7.37M 0.02% 895
2016
Q2 		$1.79M Buy
+23,001
New +$1.96M ﹤0.01% 1889

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Acquisition's BMRN Position: Q3 2016 in Review

Emerald Acquisition increased its BioMarin Pharmaceuticals (BMRN) stake by 340% in Q3 2016, buying an estimated $7.37M and bringing the position to 101,253 shares worth $9.37M. The position accounts for 0.02% of the portfolio, ranked #895.

Emerald Acquisition first reported a position in BMRN in Q2 2016 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

  • Emerald Acquisition held 101,253 shares of BioMarin Pharmaceuticals worth $9.37M as of Q3 2016.
  • Emerald Acquisition bought 78,252 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $7.37M.
  • BioMarin Pharmaceuticals made up 0.02% of Emerald Acquisition's portfolio in Q3 2016, its #895 holding.
  • Emerald Acquisition first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 422 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.